THE WOODLANDS, Texas, June 27, 2011 /PRNewswire/ — Lexicon Pharmaceuticals, Inc.
(Nasdaq:
LXRX), a biopharmaceutical company focused on discovering
breakthrough treatments for human disease, announced today that the
company presented clinical data from a mechanistic study of LX4211,
a dual inhibitor of sodium glucose transporters 1 and 2 (SGLT1 and
SGLT2), in patients with type 2 diabetes at the 71st Scientific
Sessions of the American Diabetes Association (ADA) in San Diego,
California. In addition, the company announced that it has
commenced enrollment of patients with type 2 diabetes in its Phase
2b clinical trial of LX4211.
Data from the mechanistic study demonstrated that a single dose
of LX4211 significantly increased circulating levels of GLP-1
(active and total) and PYY, important regulators of glycemic and
appetite control. For more information on this program or to
download a copy of the poster from the ADA meeting, please visit www.lexpharma.com.
The Phase 2b trial is a randomized, double-blind, placebo
controlled study of LX4211 in approximately 285 adult patients
(18-75 years) with type 2 diabetes who are not adequately
controlled on metformin monotherapy. Patients will be
administered LX4211 in combination with standard metformin therapy
over 12 weeks. Doses will include 75 mg once daily, 200 mg
once daily, 200 mg twice daily, 400 mg once daily or placebo.
The primary endpoint of the study is the change from baseline
in HbA1c at Week 12. Secondary endpoints will include
percentage of patients achieving HbA1c < 7%, and changes in
fasting plasma glucose, 3-hour glucose tolerance test, weight,
blood pressure, and triglycerides. The study will be
conducted at ap
‘/>”/>
SOURCE
